Crown Reserve Sets Dec 22 Vote on Extension to Complete Carvix Deal
CRAC is trading near its 52-week low of $9.89 (3.9% above the low) on elevated volume (4.8× avg).
Summary
Crown Reserve scheduled a December 22, 2026 shareholder vote to extend its business-combination deadline beyond February 10, 2027, giving it time to close the Carvix merger. Public shareholders can redeem at trust value whether or not they vote for the extension.
Key Events · Corporate Governance and Compliance · CRAC
-
Extension Vote Set for December 22
Shareholders will vote on a special resolution to move the business-combination deadline from February 10, 2027 to a later date, with the record date fixed at November 16, 2026.
-
Redemption Window Opens
Public holders may elect to redeem at the per-share trust value regardless of how they vote; the election deadline is 5:00 p.m. Eastern on December 18, 2026.
-
Liquidation Risk if Extension Fails
Without approval, the company must cease operations, redeem public shares and dissolve if no deal closes by February 10, 2027; warrants and rights would expire worthless.
-
Carvix Deal Still Pending
The March 30, 2026 business combination agreement with Carvix, as amended August 26 and September 23, 2026, has not closed and is not being voted on at this meeting.
Analysis · CRAC · Trade & Services
Crown Reserve is asking shareholders to push its business-combination deadline past February 10, 2027 so it can close the Carvix merger, which it currently believes it cannot finish in time. The vote is a survival test: if the extension fails and no deal closes by February 10, 2027, the company must wind up and redeem public shares, and its warrants and rights expire worthless. Public holders get a redemption option at the trust value regardless of how they vote, so the key variable is how many shares elect out — heavy redemptions could leave too little cash to satisfy the deal's minimum cash condition.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRAC was trading at $10.28 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $230M. The 52-week trading range was $9.89 to $10.30. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.